# OnCo record paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023" ;
  schema:name "Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer"@en ;
  schema:description "A Spanish trial of 86 patients with stage III lung cancer. Adding immunotherapy before surgery left 37 percent with no viable tumour in the specimen against 7 percent, and 85 percent were alive at two years against 64."@en ;
  schema:url <https://onco.cc/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2215530>, <https://pubmed.ncbi.nlm.nih.gov/37379158/>, <https://clinicaltrials.gov/study/NCT03838159> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2215530> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Provencio M, Nadal E, Gonzalez-Larriba JL, et al." ;
  onco:related <https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/>, <https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/>, <https://onco.cc/key-papers/paper-keynote-671-n-engl-j-med-2023/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/surgery/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/terms/immune-checkpoint/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .